BRCA1 and breast cancer: Since poly ADP-ribose polymerase (PARP) is also essential in DNA repair, PARP inhibitors (PARPis) cause synthetic lethality in tumors with BRCA1 and/or BRCA2 germline mutations and are used for ovarian, prostate, pancreatic, and breast cancer.